Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07294677 · ClinicalTrials.gov registry record · Phase 1

CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL

A Phase 1 study of Lymphoma and Leukemia, sponsored by University of Chicago.

Recruiting
Registry status
Phase 1
Development phase
104
Enrollment target
1
Study location

NCT07294677 is a Phase 1 study of Lymphoma and Leukemia that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 104 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07294677, a Phase 1 study of Lymphoma and Leukemia, is actively recruiting participants, sponsored by University of Chicago.

RECRUITING
Registry status
Phase 1
Development phase
104 participants
Enrollment target
1
Study location

Study Summary

This is a 3-part study to assess the safety of adding capivasertib to a standard of care treatment regimen consisting of venetoclax and low-intensity chemotherapy. This chemotherapy regimen called mini-hyperCVD consists of the chemotherapy drugs, cyclophosphamide, vincristine, dexamethasone; (part A) alternating with high-dose methotrexate and cytarabine (part B) administered approximately every 28 days. In the first part of the study (Cohort 1), the study seeks to determine the recommended dose of capivasertib that can be safely given with venetoclax and chemotherapy. Several doses of capivasertib may be tested in small groups of subjects in this part of the study. The dose tested will be increased or lowered depending on types and frequency of side effects seen until the best, safe dose is found. Once the recommended, safe dose of capivasertib is found, the study will move on to the second part (Cohort 2) and will treat additional participants to learn more about the safety of giving these drugs together. If the combination is determined to be safe overall, the study will move on to the third part (Cohort 3). In this part of the study, participants will be randomized to receive the mini-hyperCVD and venetoclax alone or with capivasertib.

Conditions Studied

Lymphoma Leukemia

Interventions

  • DRUG Venetoclax
  • DRUG Rituximab
  • DRUG Blinatumomab
  • DRUG Capivasertib
  • DRUG Nelarabine

Study Locations (1)

Illinois

  • University of Chicago Medicine Comprehensive Cancer Center - Chicago

Trial Details

FieldValue
Enrollment Target 104 participants
Start Date 2026-03-17
Est. Completion 2032-03
Phase Phase 1

Sponsor

University of Chicago

796 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07294677

The ClinicalTrials.gov registry entry for NCT07294677 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (78% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Venetoclax is the first listed.

NCT07294677 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT07294677 about?

NCT07294677 is a clinical study titled "CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL". This is a 3-part study to assess the safety of adding capivasertib to a standard of care treatment regimen consisting of venetoclax and low-intensity chemotherapy. This chemotherapy regimen called mini-hyperCVD consists of the chemotherapy drugs, cyclophosphamide, vincristine, dexamethasone; (part A...

What is the current status of trial NCT07294677?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 104 participants. The study started on 2026-03-17. Estimated completion is 2032-03.

What conditions does trial NCT07294677 study?

This clinical trial studies the following conditions: Lymphoma, Leukemia.

What interventions are being tested in trial NCT07294677?

The interventions under investigation include: Venetoclax (DRUG), Rituximab (DRUG), Blinatumomab (DRUG), Capivasertib (DRUG), Nelarabine (DRUG).

Who is sponsoring clinical trial NCT07294677?

This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07294677 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lymphoma

All registered trials for this condition

Leukemia

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.